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Abstract
Background: Matrix metalloproteinases (MMPs) are proteolytic enzymes that may contribute to
tissue destruction in Sjögren's syndrome (SS). Low-dose doxycycline (LDD) inhibits MMPs. We
evaluated the efficacy of LDD for the subjective symptoms in primary SS patients.
This was a randomized, double blind, placebo controlled cross-over study. 22 patients were
randomly assigned to receive either 20 mg LDD or matching placebo twice a day for 10 weeks. The
first medication period was followed by 10-week washout period, after which the patient received
either LDD or placebo, depending on the first drug received, followed by the second washout
period. Stimulated saliva flow rates and pH were measured before and after one and ten weeks of
each medication and after washout periods. VAS scale was used to assess the effect of LDD and
placebo on following six subjective symptoms: xerostomia; xerophtalmia; difficulty of swallowing;
myalgia; arthralgia; and fatigue. The effect was evaluated for each medication and washout period
separately.
Results: Overall, the effects of medications on subjective symptoms were minor. Wilcoxon test
demonstrated increased fatigue with LDD during medication (p < 0.05). The differences may,
however, reflect normal fluctuation of symptoms in SS patients.
Conclusion: LDD may not be useful in reducing the primary SS symptoms.
Background
Sjögren syndrome (SS) is a slowly progressing autoim-
mune rheumatic disease with unknown etiology [1]. It is
associated with symptoms of xerostomia and xerophtal-
mia, and mononuclear cell infiltration of exocrine glands.
Arthralgia, myalgia, Raynaud's phenomenon and fatigue
are the most common systemic manifestations of SS. SS
can be divided into primary and secondary forms. Primary
SS is defined by the presence of salivary and lacrimal
gland involvement as a sole systemic disorder. The course
Published: 31 December 2007
Journal of Negative Results in BioMedicine 2007, 6:11 doi:10.1186/1477-5751-6-11
Received: 21 May 2007
Accepted: 31 December 2007
This article is available from: http://www.jnrbm.com/content/6/1/11
© 2007 Seitsalo et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Negative Results in BioMedicine 2007, 6:11 http://www.jnrbm.com/content/6/1/11
Page 2 of 6
(page number not for citation purposes)
of the disease is often stable with slow initiation and
progression of sicca symptoms. Primary SS is a separate
disease entity, while secondary SS is concurrent with
another rheumatic disease [1]. The prevalence of primary
SS is estimated to be 0.6–4.0% of the world's population.
About 90% of the patients are women, usually in their
fifth or sixth decade. Because of the slow development of
the symptoms, it is generally underdiagnosed [2-4].
Matrix metalloproteinases (MMPs) constitute a family of
zinc-containing endoproteinases with 23 members. The
principal function of MMPs is the proteolytic degradation
of connective tissue matrix proteins, and in concert they
can degrade practically all extracellular matrix proteins
[5]. MMPs participate in the physiologic tissue regenera-
tion, as in the wound healing, but they are also involved
in the pathological conditions such as periodontitis, rheu-
matoid arthritis, other inflammatory diseases, and in the
growth of tumors and cancer [5-9]. MMP expression and
catalytic activity are increased in tissue samples from SS
patients [10,11] and correlate with the severity of the dis-
ease and structural and functional glandular changes [10].
Primary SS patients exhibit increased plasma MMP-9 lev-
els, which has been suggested to indicate definite primary
SS [12]. SS patients' saliva contains increased concentra-
tions of at least MMP-9, which is at least in part of glandu-
lar origin [13-15]. The increased salivary MMP-9 levels in
relation to the endogenous tissue inhibitor of matrix
metalloproteinase-1 (TIMP-1) have also been shown in
primary SS patients [15].
The effect of medication targeting the potential factors
behind the pathogenesis of SS on subjective symptoms
has recently been a focus of interest in several studies
[16,17], but the results have not been very promising. Due
to their tissue-destructive capacity in chronic inflamma-
tory diseases MMPs have been suggested as a potential tar-
get of action in the treatment of SS [13], including salivary
glands [18,19].
Tetracyclines are antimicrobial agents, inhibiting also
MMPs with a mechanism which is independent from their
antimicrobial effect [20]. Doxycycline given in low doses
(low-dose doxycycline, LDD) decreases significantly MMP
activity by multiple mechanisms in the inflammatory dis-
eases with no noticeable antimicrobial effects [21].
Based on the earlier studies a hypothesis was formed that
through its MMP-inhibitory action, LDD could be effec-
tive in treatment of SS by decreasing the tissue damage
and therefore also the subjective symptoms of the
patients. The aim of this study was to evaluate the effec-
tiveness of LDD on clinical symptoms of SS in a rand-
omized, double-blinded, placebo-controlled clinical
cross-over trial.
Results
Seventeen subjects out of 22 patients included at the onset
of the study (77%) completed the study and provided the
VAS score data after each medication and washout period.
The stimulated salivary flow rates and pH were low com-
pared to normal reference values (salivary flow > 0,7 ml/
min, pH 7,3 for stimulated saliva) (Figure 1). No statisti-
cally significant differences were observed between any
time points (Wilcoxon signed ranks test).
In Figure 2 the VAS score distribution of the LDD and pla-
cebo medication periods for two symptoms (xerostomia
and fatigue) are presented as descriptive plot figures. The
plots demonstrate remarkably similar distribution of VAS
scores for LDD and placebo throughout both medication
periods, with no apparent changes during either medica-
tion or between the medications. With the other symp-
toms evaluated, similar distribution of scores was
observed (data not shown).
Comparison of the VAS scores between the pre-medica-
tion and seven-week medication demonstrated statisti-
cally significantly higher values for myalgia after seven
weeks of both LDD and placebo (Figure 3). Comparison
of the VAS scores between LDD and placebo after seven
weeks of medication demonstrated statistically signifi-
cantly higher VAS scores for fatigue after LDD medication
(Figure 3) (p < 0.05 in both cases: Wilcoxon signed ranks
test).
Post-experimental interview
For the post-experimental telephone interview, 16
patients were reached. Five patients had experienced
significant alleviation of symptoms during one of the
Stimulated saliva pH and salivary flow rate during the experi- ment Figure 1
Stimulated saliva pH and salivary flow rate during 
the experiment. There were no statistically significant dif-
ferences between any of the time points either in pH or sali-
vary flow values (Wilcoxon sign-rank test).Journal of Negative Results in BioMedicine 2007, 6:11 http://www.jnrbm.com/content/6/1/11
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medication periods. Three patients had felt the benefits
during the LDD medication and two had felt the benefits
during placebo medication.
Discussion
In spite of tissue destructive nature of primary SS, the sub-
jective symptoms are the most significant handicap.
Therefore development of palliative treatment strategies
has long been an object of interest. Local treatments, such
as artificial saliva or lozenges, are insufficient and provide
only temporary relief [22,23]. Pilocarpine is the only
widely accepted systemic treatment method that has been
shown to be effective [24], but the severe side effects and
unpredictability of clinical response limit its use [25].
Cevimeline, a quinuclidine derivative of acetylcholine
receptors, has been indicated to alleviate subjective symp-
toms without significant side effects [22], but further
research is needed before the wide use of this drug can be
substantiated. Therefore a need for effective, safe and prac-
tical systemic treatment measures to alleviate the subjec-
tive symptoms associated with primary SS still exists.
Ideally, relief of subjective symptoms should occur con-
comitantly with reduced tissue destruction. As low-dose
doxycycline has recently been shown to reduce both the
recurrence of oral aphthous ulceration and subjective
experience of pain in recurrent oral aphthous ulceration
(ROAU) patients [26], the palliative effect of LDD also in
SS patients could be expected.
The low salivary flow rate and low saliva pH were
expected, as values of this kind are normally found in SS
patients with established disease. Measuring the unstimu-
lated salivary flow rate proved impossible due to practi-
cally zero unstimulated saliva secretion in most patients.
The findings indicate the severe condition of SS in the sub-
jects involved in the study.
Overall, the changes in the subjective symptoms within
the LDD or placebo medication or washout periods were
small and most likely reflect the usual fluctuation of
symptoms rather than true differences caused by medica-
tion. Considering the subjective symptoms that exhibited
statistically significant differences within specific medica-
tion or washout, only the increase in fatigue with LDD
medication seems possibly clinically significant
(Figure 3). Muscle pain as a possible side effect has been
described in the Periostat Prescribing Information sheet,
but the percentage of incidence (1%) is lower than with
the placebo group (3%). Also the other pain-related
adverse reactions with Periostat medication are low. Con-
sidering the fact that statistically significant rise in myalgia
VAS scores was detected also in the LDD washout period
and in placebo medication period when comparing the
first and seventh week VAS scores (Figure 3), it is possible
that even with the sharp increase in VAS pain score after
Plot figures of individual VAS scores Figure 2
Plot figures of individual VAS scores. Plot figures of 
individual VAS scores of xerostomia and fatigue during the 
LDD medication period (expressed as positive values above 
x-axis) and respective placebo period (expressed as negative 
values below the x-axis). No apparent effect on any of the 
subjective symptoms recorded was seen during either one of 
the medications. Similar distribution of scores was observed 
for the other symptoms (data not shown).
VAS scores of measured subjective symptoms in weeks one  and seven Figure 3
VAS scores of measured subjective symptoms in 
weeks one and seven. * indicates statistically significant 
differences between the observation time points (p < 0.05; 
Wilcoxon signed test).Journal of Negative Results in BioMedicine 2007, 6:11 http://www.jnrbm.com/content/6/1/11
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5th week of Periostat medication the finding may be a
coincidence. This is supported by the post-experimental
interview, which clearly indicated that there was no over-
all effect on subjective symptoms by LDD. On the other
hand, taking into consideration the multi-dimensional
subjective symptomology of SS patients, with mostly
unknown pathology behind the symptoms, it is possible
that MMP inhibition might in some way increase the sub-
jective feeling of myalgia. The lack of clinically significant
findings in this study may also be affected by the low
numer of patients (22 patients) involved, even though all
the patients in the patient records of Northern Ostroboth-
nia Hospital District (Oulu University Hospital, covering
12 % of Finland's surface area) with SS diagnosis were
included into screening. Another study with larger patient
population, requiring multi-center study, would be
needed for the final conclusion in this matter. However,
since the positive effects of LDD medication on SS subjec-
tive symptoms seem to be minor, larger-scale studies with
SS patients, at least the patients with established disease as
in this study, do not seem justified.
Conclusion
MMP inhibition with LDD was not effective in alleviating
the subjective symptoms of primary SS patients with
already established disease. The finding is concurrent with
the other studies aiming at the reduction of symptoms by
directing the systemic medication against potential patho-
genetic factors [16,17], with the possible exception of
cemiveline hydrochloride [22]. This study does not
exclude the possibility of beneficial effect of MMP inhibi-
tion on slowing down or inhibiting the MMP-mediated
tissue destruction at least in secretory glands
[10,11,13,18,19]. However, since the disease is usually
diagnosed only after advanced gland tissue destruction
has already occurred, sensible and specific diagnostic
methods to screen the primary SS patients before the
development of subjective symptoms would be needed
before the preventive treatment can be provided. Also,
recent study indicating that MMP-9 may actually have a
protective role against eruption of purpura and develop-
ment of autoantibody reaction in primary SS [12], signify
the importance of fundamental understanding of MMPs
in SS pathogenesis before interceptive treatment can be
justified in symptomless patients.
Methods
Detailed description of the patient inclusion and exclu-
sion criteria has been presented previously [27]. Briefly,
consecutive outpatients with existing diagnosis of primary
SS from the Department of Rheumatology in Oulu Uni-
versity Hospital, Oulu, Finland, constituted the patient
group. For the diagnosis of primary SS the patient had to
fulfil the revised European Community proposed criteria
[28]. Approval for the study protocol was obtained from
the Oulu University Hospital Ethical Committee and
from the National Agency for Medicines. All the patients
gave their written informed consent. A total of 44 patients
were screened, 27 patients were qualified to participate
and 22 patients chose to enter the study. All the patients
were women.
This was a randomized, double blind, placebo-controlled
clinical trial, and the patients were randomized at the
baseline. Randomization was performed by use of a com-
puter-generated list, and the drug and placebo were indis-
tinguishable in appearance, smell and taste. Neither the
person in charge of clinical protocol of the study nor the
patients were aware of the treatment assignments.
At the onset of the study, the patients underwent a thor-
ough oral and dental examination as a part of normal
dental treatment. One of the patients had gingivitis. Some
patients had a few secondary caries lesions or primary cer-
vical caries lesions. The normal dental treatment was pro-
vided at the onset of the study according to the need. The
patients were randomly assigned to receive either low-
dose doxycycline (20 mg doxycycline; Periostat®; further
referred as LDD) or matching placebo (both from Colla-
Genex Pharmaceuticals, Inc. Newtown, PA, USA) twice a
day for a period of 10 weeks (Medication 1; see Figure 4).
The first medication period was followed by 10-week
washout period (Washout 1; Figure 4), after which the
patient received either LDD or placebo, depending on the
first drug received (Medication 2; Figure 4), followed by
the second washout period. Stimulated and unstimulated
saliva was collected, and flow rate and pH were measured
at the onset and after one and 10 weeks of each medica-
tion period, as well as after 10-week washout periods.
To assess the effect of LDD and placebo on subjective
symptoms, six 100-mm Visual Analog Scale forms (VAS;
form identical to those used to describe pain) were used
to describe the intensity of the following symptoms:
xerostomia; xerophtalmia; difficulty of swallowing; myal-
gia; arthralgia; and fatigue. The patients were instructed to
provide a VAS rating every week at the same time of the
week for each of the six symptoms, using a range from 0
for the total absence of symptom to 100 for worst imagi-
nable symptom. After each medication and washout
period the VAS score sheets were collected (Figure 4) and
new score sheets provided for the next period.
Six months after the experiment the patients were con-
tacted by telephone and asked for their subjective opinion
whether the drug provided any help in general for their
subjective symptoms or not (post-experimental inter-
view) (Figure 4).Journal of Negative Results in BioMedicine 2007, 6:11 http://www.jnrbm.com/content/6/1/11
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Statistical analysis
SPSS for Windows Release 11.5.1 (SPSS Inc., Chicago, IL,
USA) was used for the statistical analysis. Since the
number of the marked scores decreased towards the end
of each medication and washout period (because of
apparent reduction of co-operation towards the end of
each period), the statistical analysis was only extended to
the 7th week of each period. Wilcoxon signed ranks test
for two related variables was used to analyse the differ-
ences between the pre-medication and 7-week medication
samples within both medication regimens, and between
the values after 7-week LDD and 7-week placebo medica-
tions, to evaluate the possible effect of LDD on subjective
symptoms. The same test was also used to examine the
differences between the pre-medication levels, to exclude
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